Ironwood Income Statement Research

IRWD Stock

USD 8.06 0.14 1.77%

Most accounts from Ironwood Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Ironwood Pharmaceuticals Valuation and Ironwood Pharmaceuticals Correlation analysis.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M.

	2021	2022	2023	2024 (projected)
Interest Expense	31.2M	7.6M	21.6M	19.9M
Depreciation And Amortization	682K	9.5M	1.6M	1.5M

Interest Expense Depreciation And Amortization

Ironwood Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Interest Income	Net Interest Income	Discontinued Operations	Reconciled Depreciation	Extraordinary Items	Tax Provision
Depreciation And Amortization		-0.2	-0.3	-0.31	-0.01	-0.39	-0.41	-0.04	-0.38	0.02	-0.01	0.27	0.41	0.2	0.08	-0.1	0.18	-0.08	0.13	0.32	-0.28	-0.21	0.3	-0.21	0.2
Interest Expense	-0.2		0.53	0.5	0.74	-0.01	0.04	0.6	0.04	-0.47	0.75	-0.02	-0.02	0.02	-0.1	0.81	0.04	-0.39	0.14	-0.68	-0.11	0.02	-0.11	0.02	-0.24
Total Revenue	-0.3	0.53		1.0	0.34	0.67	0.74	0.09	0.74	-0.46	0.35	0.04	-0.27	0.06	-0.05	0.57	0.08	-0.12	0.09	-0.85	0.48	0.53	-0.73	0.53	-0.14
Gross Profit	-0.31	0.5	1.0		0.29	0.71	0.77	0.05	0.77	-0.47	0.31	0.05	-0.28	0.07	-0.06	0.52	0.09	-0.09	0.05	-0.83	0.5	0.56	-0.75	0.56	-0.15
Other Operating Expenses	-0.01	0.74	0.34	0.29		-0.36	-0.28	0.91	-0.28	-0.32	1.0	-0.18	-0.01	-0.19	0.18	0.95	-0.18	-0.31	0.45	-0.5	-0.14	-0.41	0.21	-0.41	0.11
Operating Income	-0.39	-0.01	0.67	0.71	-0.36		0.98	-0.51	0.98	-0.3	-0.34	-0.05	-0.47	-0.02	-0.06	-0.1	0.0	0.2	-0.4	-0.42	0.73	0.89	-0.93	0.89	-0.11
Ebit	-0.41	0.04	0.74	0.77	-0.28	0.98		-0.44	1.0	-0.3	-0.26	-0.07	-0.5	-0.04	-0.07	-0.02	-0.02	0.18	-0.21	-0.49	0.75	0.81	-0.95	0.81	-0.11
Research Development	-0.04	0.6	0.09	0.05	0.91	-0.51	-0.44		-0.45	-0.14	0.91	-0.3	-0.04	-0.3	0.21	0.79	-0.3	-0.27	0.44	-0.27	-0.29	-0.6	0.44	-0.6	0.15
Ebitda	-0.38	0.04	0.74	0.77	-0.28	0.98	1.0	-0.45		-0.3	-0.27	-0.06	-0.49	-0.03	-0.07	-0.02	-0.01	0.18	-0.21	-0.48	0.75	0.81	-0.95	0.81	-0.11
Cost Of Revenue	0.02	-0.47	-0.46	-0.47	-0.32	-0.3	-0.3	-0.14	-0.3		-0.36	0.13	0.24	0.1	0.02	-0.44	0.1	-0.09	0.14	0.34	-0.34	-0.34	0.4	-0.34	0.05
Total Operating Expenses	-0.01	0.75	0.35	0.31	1.0	-0.34	-0.26	0.91	-0.27	-0.36		-0.18	-0.02	-0.2	0.18	0.96	-0.19	-0.28	0.43	-0.51	-0.13	-0.4	0.2	-0.4	0.1
Income Before Tax	0.27	-0.02	0.04	0.05	-0.18	-0.05	-0.07	-0.3	-0.06	0.13	-0.18		0.9	0.97	-0.41	-0.17	0.97	-0.35	-0.12	-0.26	-0.56	0.11	0.16	0.11	-0.44
Total Other Income Expense Net	0.41	-0.02	-0.27	-0.28	-0.01	-0.47	-0.5	-0.04	-0.49	0.24	-0.02	0.9		0.86	-0.32	-0.12	0.86	-0.38	-0.01	-0.03	-0.81	-0.27	0.55	-0.27	-0.34
Net Income	0.2	0.02	0.06	0.07	-0.19	-0.02	-0.04	-0.3	-0.03	0.1	-0.2	0.97	0.86		-0.6	-0.19	1.0	-0.32	-0.11	-0.28	-0.57	0.12	0.11	0.12	-0.63
Income Tax Expense	0.08	-0.1	-0.05	-0.06	0.18	-0.06	-0.07	0.21	-0.07	0.02	0.18	-0.41	-0.32	-0.6		0.19	-0.59	0.06	-0.06	0.14	0.34	-0.08	0.07	-0.08	0.97
Selling General Administrative	-0.1	0.81	0.57	0.52	0.95	-0.1	-0.02	0.79	-0.02	-0.44	0.96	-0.17	-0.12	-0.19	0.19		-0.17	-0.24	0.38	-0.68	0.07	-0.2	-0.04	-0.2	0.1
Net Income From Continuing Ops	0.18	0.04	0.08	0.09	-0.18	0.0	-0.02	-0.3	-0.01	0.1	-0.19	0.97	0.86	1.0	-0.59	-0.17		-0.35	-0.12	-0.29	-0.56	0.14	0.09	0.14	-0.63
Non Operating Income Net Other	-0.08	-0.39	-0.12	-0.09	-0.31	0.2	0.18	-0.27	0.18	-0.09	-0.28	-0.35	-0.38	-0.32	0.06	-0.24	-0.35		-0.12	0.16	0.51	0.02	-0.15	0.02	0.18
Non Recurring	0.13	0.14	0.09	0.05	0.45	-0.4	-0.21	0.44	-0.21	0.14	0.43	-0.12	-0.01	-0.11	-0.06	0.38	-0.12	-0.12		-0.14	-0.1	-0.64	0.2	-0.64	0.02
Interest Income	0.32	-0.68	-0.85	-0.83	-0.5	-0.42	-0.49	-0.27	-0.48	0.34	-0.51	-0.26	-0.03	-0.28	0.14	-0.68	-0.29	0.16	-0.14		-0.16	-0.3	0.45	-0.3	0.26
Net Interest Income	-0.28	-0.11	0.48	0.5	-0.14	0.73	0.75	-0.29	0.75	-0.34	-0.13	-0.56	-0.81	-0.57	0.34	0.07	-0.56	0.51	-0.1	-0.16		0.54	-0.79	0.54	0.36
Discontinued Operations	-0.21	0.02	0.53	0.56	-0.41	0.89	0.81	-0.6	0.81	-0.34	-0.4	0.11	-0.27	0.12	-0.08	-0.2	0.14	0.02	-0.64	-0.3	0.54		-0.85	1.0	-0.15
Reconciled Depreciation	0.3	-0.11	-0.73	-0.75	0.21	-0.93	-0.95	0.44	-0.95	0.4	0.2	0.16	0.55	0.11	0.07	-0.04	0.09	-0.15	0.2	0.45	-0.79	-0.85		-0.85	0.1
Extraordinary Items	-0.21	0.02	0.53	0.56	-0.41	0.89	0.81	-0.6	0.81	-0.34	-0.4	0.11	-0.27	0.12	-0.08	-0.2	0.14	0.02	-0.64	-0.3	0.54	1.0	-0.85		-0.15
Tax Provision	0.2	-0.24	-0.14	-0.15	0.11	-0.11	-0.11	0.15	-0.11	0.05	0.1	-0.44	-0.34	-0.63	0.97	0.1	-0.63	0.18	0.02	0.26	0.36	-0.15	0.1	-0.15

Click cells to compare fundamentals

Ironwood Pharmaceuticals Account Relationship Matchups

Ironwood Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	36.6M	29.5M	31.2M	7.6M	21.6M	19.9M
Total Revenue	428.4M	389.5M	413.8M	410.6M	442.7M	231.7M
Gross Profit	404.5M	386.4M	412.2M	409.2M	441.2M	224.0M
Operating Income	120.1M	142.9M	232.3M	250.3M	209.0M	219.5M
Ebit	120.1M	142.9M	232.3M	250.3M	209.0M	219.5M
Research Development	115.0M	88.1M	70.4M	44.3M	99.4M	107.6M
Ebitda	120.4M	159.9M	232.9M	259.8M	210.6M	221.1M
Cost Of Revenue	23.9M	3.1M	1.5M	1.4M	1.6M	1.5M
Income Before Tax	58.9M	108.9M	200.7M	252.4M	(948.1M)	(900.7M)
Net Income	(15.3M)	106.2M	528.4M	175.1M	(1.0B)	(952.1M)
Income Tax Expense	74.3M	2.7M	(327.8M)	77.4M	83.5M	87.7M
Non Recurring	309K	167.7M	3.6M	15.4M	17.7M	16.8M
Interest Income	2.9M	1.5M	726K	9.5M	23.2M	24.4M
Net Interest Income	(33.7M)	(28.0M)	(30.4M)	1.9M	8.5M	8.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:

How To Invest In Ironwood

Details

Is Ironwood Stock a good investment?

Details

What is Ironwood Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Ironwood Pharmaceuticals Valuation and Ironwood Pharmaceuticals Correlation analysis.

For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	CEOs Directory Screen CEOs from public companies around the world
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Fundamental Analysis View fundamental data based on most recent published financial statements
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk

Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.69)

Earnings Share

(6.45)

Revenue Per Share

2.848

Quarterly Revenue Growth

0.097

Return On Assets

0.1339

The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ironwood Income Statement Research

Ironwood Pharmaceuticals income statement Correlations

Ironwood Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ironwood Pharmaceuticals income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Ironwood Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Net Income
Extraordinary Items	+ 1.0	Discontinued Operations
Ebit	+ 0.98	Operating Income

Reconciled Depreciation	- 0.95	Ebitda
Reconciled Depreciation	- 0.95	Ebit
Reconciled Depreciation	- 0.93	Operating Income
Extraordinary Items	- 0.85	Reconciled Depreciation
Reconciled Depreciation	- 0.85	Discontinued Operations
Interest Income	- 0.85	Total Revenue